Radicicol is a macrocyclic antifungal compound that functions as a potent inhibitor of HSP90, a molecular chaperone involved in protein folding and stability. In neuroscience, Radicicol's ability to bind HSP90 and disrupt its interaction with client proteins offers a mechanism for modulating neurodegenerative disease pathways. It selectively depletes kinases such as Raf and inhibits src-like kinases, contributing to the regulation of cellular stress responses and apoptosis. Radicicol also exhibits anti-angiogenic properties and induces morphological reversion in transformed cells, which may be relevant in neuro-oncology. Its strong binding affinity to HSP90 across species, including yeast and bacterial homologs, underscores its utility in translational research models. By targeting chaperone-mediated proteostasis, Radicicol holds promise for therapeutic intervention in disorders characterized by protein misfolding and aggregation.